Abstract: Abstract: Non-Hodgkin lymphoma (NHL) is the most common hematological malignancy, and the prognosis of patients with relapse and refractory is poor. Chimeric antigen receptor T-cell immunotherapy (CAR-T) is a new immunotherapy method in recent years, which has made many breakthroughs in the treatment of malignant tumors, especially hematological tumors. In particular, there is hope for patients with relapsed and refractory B-cell NHL. At present, Food and Drug Administration (FDA) has approved two CAR-T cell therapy tisagenlecleucel and axicabtagene ciloleucel. Several other products are still in clinical trials. This article reviews the structure of CAR-T and its efficacy, safety and research trends in common B-cell NHL

Key words: lymphoma, immunotherapy, review, chimeric antigen receptor T cell